← Leaderboards
Stuart E Starr
Children'S Hospital Of Philadelphia
$1,873,719
Attributed
$1,873,719
Total exposure
9
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,873,719 · 9
By mechanism
U01$1,686,474 · 1
M01$187,245 · 8
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Katherine A High$15,374,120
- Valder R Arruda$13,574,051
- Haig H. Kazazian$23,355,580
- Catherine S Manno$745,950
- Alan R. Cohen$10,567,103
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationHiv InfectionsAids TherapyChild (0-11)Pediatric AidsClinical Trial Phase IAids VaccinesClinical TrialsOutcomes ResearchImmunotherapyAids Education /PreventionNevirapineHuman Immunodeficiency Virus 1Drug Screening /EvaluationVertical TransmissionPediatric PharmacologyPharmacokineticsAntiviral AgentsCombination ChemotherapyAntiaids AgentChemopreventionCytomegalovirus
Grant awards (18)
ACTG377--ANTIRETROVIRAL REGIMENS W/ COMBOS OF PROTEASE INHIBITORS$186,685
M01 · FY2002 · RR
HIV VACCINE, AIDSVAX B/B IN CHILDREN OF HIV+ MOTHERS$0
M01 · FY2002 · RR
PHASE I/II TRIAL OF CD4-IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 382--DMP 266 IN COMBINATION WITH NELFINAVIR IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 316--NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL/FETAL HIV$0
M01 · FY2002 · RR
SAFETY AND IMMUNOGENICITY OF CANARYPOX CMV (VCP260) IN HEALTHY ADULTS$0
M01 · FY2002 · RR
ACT 299--RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 265--LIVE ATTENTUATED VARICELLA VACCINE IN HIV INFECTION CHILDREN$0
M01 · FY2002 · RR
PHILADELPHIA PEDIATRIC AIDS CLINICAL TRIALS UNIT$890,498
U01 · FY2001 · AI
PHILADELPHIA PEDIATRIC AIDS CLINICAL TRIALS UNIT$795,976
U01 · FY2000 · AI
ACTG377--ANTIRETROVIRAL REGIMENS W/ COMBOS OF PROTEASE INHIBITORS$560
M01 · FY2000 · RR
PHASE I/II TRIAL OF CD4-IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 382--DMP 266 IN COMBINATION WITH NELFINAVIR IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 316--NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL/FETAL HIV$0
M01 · FY2000 · RR
SAFETY AND IMMUNOGENICITY OF CANARYPOX CMV (VCP260) IN HEALTHY ADULTS$0
M01 · FY2000 · RR
ACT 299--RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 265--LIVE ATTENTUATED VARICELLA VACCINE IN HIV INFECTION CHILDREN$0
M01 · FY2000 · RR
HIV VACCINE, AIDSVAX B/B IN CHILDREN OF HIV+ MOTHERS$0
M01 · FY2000 · RR